Allworth Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Allworth Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.8K	Buy	4,816 +913	+23%	+$3.53K	﹤0.01%	3206
2025 Q4	$16K	Sell	3,903 -5,645	-59%	-$28K	﹤0.01%	2953
2025 Q3	$46.6K	Buy	9,548 +4,403	+86%	+$23.1K	﹤0.01%	2139
2025 Q2	$26K	Buy	5,145 +1,221	+31%	+$6K	﹤0.01%	2355
2025 Q1	$22.6K	Buy	3,924 +2,529	+181%	+$18.4K	﹤0.01%	2006
2024 Q4	$10.4K	Buy	1,395 +1,329	+2,014%	+$8.94K	﹤0.01%	2420
2024 Q3	$435	Buy	66 +5	+8%	+$36	﹤0.01%	3448
2024 Q2	$465	Buy	61 +26	+74%	+$227	﹤0.01%	3388
2024 Q1	$349	Hold	35	–	–	﹤0.01%	3372
2023 Q4	$346	Sell	35 -15	-30%	-$107	﹤0.01%	3208
2023 Q3	$383	Buy	50 +15	+43%	+$150	﹤0.01%	3104
2023 Q2	$262	Buy	+35	New	+$245	﹤0.01%	3045

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Allworth Financial's RXRX Position: Q1 2026 in Review

Allworth Financial increased its Recursion Pharmaceuticals (RXRX) stake by 23% in Q1 2026, buying an estimated $3.53K and bringing the position to 4,816 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

Allworth Financial first reported a position in RXRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $46.6K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Allworth Financial held 4,816 shares of Recursion Pharmaceuticals worth $14.8K as of Q1 2026.
Allworth Financial bought 913 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.53K.
Recursion Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3206 holding.
Allworth Financial first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Allworth Financial's Recursion Pharmaceuticals position peaked at $46.6K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.